GDRX

GoodRx Holdings, Inc. Class A Common Stock (GDRX) | Rumor.io

GoodRx Holdings

GDRX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,592

Bullish sentiment (50-day avg)100%

Price to earnings ratio55

Market capitalization1.1B

Earnings per share0.06

Dividend yield (TTM)—

Revenue (annual)796.9M

Net income (annual)30.4M

Social

What share of all stock conversation is about GDRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jun 5

GoodRx's discount cards and online pharmacy services offer consistent discounts for certain medications.
Investing in GoodRx is considered a viable option for managing pharmaceutical costs.
Drug prices can vary significantly, even with GoodRx's discounts, making it essential to compare prices with every refill.

Generated by AI

Sentiment

Of the messages about GDRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	78.43% -10.4
Bearish	—	0%	0% 0	21.57% +10.4

Bullish· Feb 26

The market has overreacted to $GDRX's recent decline, creating a buying opportunity for long-term investors.
$GDRX's strong cash flow, profitability, and institutional ownership make it an attractive undervalued stock.
The company's pivot and adaptation efforts, combined with its untapped market potential, suggest a promising long-term outlook for $GDRX.

Bearish· Feb 26

GoodRx Holdings' shares have fallen 12% due to prescription pressures.
The company's new CEO is under fire, with some calling for her resignation and others questioning her leadership.
The stock's poor performance is attributed to a weak revenue guide, with some analysts expecting a decline in revenue.

Generated by AI

Topics

Of the messages about GDRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	2.53%
Announcements	—	—	—	76.36%
Earnings	—	—	—	3.35%
Analysts	—	—	—	8.63%
Controversies	—	—	—	0.07%
Macro	—	—	—	9.06%

Earnings· May 9

GoodRx Holdings, Inc. (GDRX) reported Q1 earnings with revenue of $203.3M, beating estimates by $2.72M, and EPS of $0.10, beating estimates by $0.02.
The company guided Q2 revenue below consensus at $190M, down from an estimated $215.62M, and stated it is unlikely to achieve its prior FY 2022 guidance.
GoodRx's stock price declined significantly after the earnings release, with a 36.5% after-hours drop, followed by a 15% decline on the next trading day.

Analysts· May 10

Barclays lowered GoodRx's price target to $15 from $28.
Multiple analysts downgraded GoodRx's rating, including RBC Capital Mkts, Raymond James, and SVB Leerink, with some cutting price targets significantly.
The consensus among analysts is mildly confident, with 76% of analysts recommending a "buy" for GoodRx.

Announcements· Feb 6

GoodRx Holdings, Inc. (GDRX) has become the integrated pricing source for Pfizer's (PFE) brand medications on TrumpRx, including over 30 essential medications.
GoodRx will power the pricing for leading brand medications on TrumpRx, offering discounted cash prices to consumers.
The partnership between GoodRx and Pfizer will provide discounted prices on 30 of Pfizer's brand-name medications, offering savings to consumers on TrumpRx.

Generated by AI

Community

Of the messages about GDRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	80%	66.67%	50%	21.7%
Newcomers	20%	33.33%	50%	78.3%

Regulars· Oct 9

GoodRx Holdings, Inc. (GDRX) is in talks with the Trump administration regarding TrumpRx participation, a new site connecting consumers to drugmakers, pharmacies, and discount programs to help lower prescription costs.
The talks have led to a significant increase in GDRX stock price, with a spike of ~17% earlier in the week, and shares are trading higher after the company's announcement.
GoodRx's success will depend on navigating the evolving market, as stated by Bank of America, and the company's shares are being closely watched for updates on the Trump administration's TrumpRx initiative.

Newcomers· Feb 7

Newcomers to the GoodRx conversation are discussing its potential for disrupting Big Pharma, with some suggesting it could be a major player in the market.
The company's recent actions, such as a possible buyback and its relationship with TrumpRx, are being closely examined by newcomers, who are questioning the motivations behind these moves.
GoodRx's value proposition, including its ability to make prescription medication more affordable, is being compared to TrumpRx, which some view as a less effective alternative.

Generated by AI

News

Amazon, GoodRx target US prescription subscribers as health insurance coverage slips

1d agoreuters.com

Mark Cuban’s Cost Plus vs. GoodRx vs. Amazon: Cheaper Prescription Options

12d agoYahoo Finance

InvestingPro Fair Value delivers 64% return on GoodRx in 5 months By Investing.com

24d agoInvesting.com

GoodRx expands family healthcare plan with 250 free medications

GoodRx, a prescription drug savings site, announced a family healthcare subscription for access to common medical services and over 250 medications.

26d agoUSA Today

GoodRx offers health subscription for families, to launch as employee benefit in 2027

26d agoReuters

GoodRx offers health subscription for families, to launch as employee benefit in 2027 By Reuters

26d agoInvesting.com

Also Discussed

Investors talking about GDRX also mention

#	Name	Attention
1	Teladoc Health Inc.TDOC	0%+0
2	American Well Corporation Class A Common StockAMWL	0%+0
3	nCino, Inc.NCNO	0%0
4	OptimizeRx CorporationOPRX	0%0
5	Royalty Pharma plc Class A Ordinary SharesRPRX	0%new
6	Marqeta Inc. Class A Common StockMQ	0%new
7	Doximity Inc. Class A Common StockDOCS	0%0
8	OSH - Oak Street Health, Inc.	——
9	KE Holdings Inc. ADRBEKE	0%new
10	ONEM - 1Life Healthcare, Inc.	——

GoodRx Holdings, Inc. Class A Common Stock

Healthcare
Health Information Services

GoodRx Holdings, Inc. Class A Common Stock represents ownership in GoodRx, a consumer-focused digital healthcare company that helps U.S. consumers compare prescription drug prices and access savings tools. GoodRx provides a price comparison platform with geographically relevant pharmacy pricing, discount codes, and prescription transaction services designed to make medication costs more transparent. The company also offers telehealth services, subscription products, and pharma manufacturer solutions that support patients, pharmacies, healthcare professionals, payers, and pharmaceutical partners. Its platform is used across the prescription marketplace to connect users with retail pharmacies and medication savings resources. Headquartered in Santa Monica, California, GoodRx operates primarily in the U.S. healthcare market, where it plays a role in digital prescription savings, healthcare information, and patient access services.

Website

Location

2701 Olympic Boulevard

Santa Monica, CA, 90404

United States

Social

What share of all stock conversation is about GDRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jun 5

GoodRx's discount cards and online pharmacy services offer consistent discounts for certain medications.
Investing in GoodRx is considered a viable option for managing pharmaceutical costs.
Drug prices can vary significantly, even with GoodRx's discounts, making it essential to compare prices with every refill.

Generated by AI

Sentiment

Of the messages about GDRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	78.43% -10.4
Bearish	—	0%	0% 0	21.57% +10.4

Bullish· Feb 26

The market has overreacted to $GDRX's recent decline, creating a buying opportunity for long-term investors.
$GDRX's strong cash flow, profitability, and institutional ownership make it an attractive undervalued stock.
The company's pivot and adaptation efforts, combined with its untapped market potential, suggest a promising long-term outlook for $GDRX.

Bearish· Feb 26

GoodRx Holdings' shares have fallen 12% due to prescription pressures.
The company's new CEO is under fire, with some calling for her resignation and others questioning her leadership.
The stock's poor performance is attributed to a weak revenue guide, with some analysts expecting a decline in revenue.

Generated by AI

Topics

Of the messages about GDRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	2.53%
Announcements	—	—	—	76.36%
Earnings	—	—	—	3.35%
Analysts	—	—	—	8.63%
Controversies	—	—	—	0.07%
Macro	—	—	—	9.06%

Earnings· May 9

GoodRx Holdings, Inc. (GDRX) reported Q1 earnings with revenue of $203.3M, beating estimates by $2.72M, and EPS of $0.10, beating estimates by $0.02.
The company guided Q2 revenue below consensus at $190M, down from an estimated $215.62M, and stated it is unlikely to achieve its prior FY 2022 guidance.
GoodRx's stock price declined significantly after the earnings release, with a 36.5% after-hours drop, followed by a 15% decline on the next trading day.

Analysts· May 10

Barclays lowered GoodRx's price target to $15 from $28.
Multiple analysts downgraded GoodRx's rating, including RBC Capital Mkts, Raymond James, and SVB Leerink, with some cutting price targets significantly.
The consensus among analysts is mildly confident, with 76% of analysts recommending a "buy" for GoodRx.

Announcements· Feb 6

GoodRx Holdings, Inc. (GDRX) has become the integrated pricing source for Pfizer's (PFE) brand medications on TrumpRx, including over 30 essential medications.
GoodRx will power the pricing for leading brand medications on TrumpRx, offering discounted cash prices to consumers.
The partnership between GoodRx and Pfizer will provide discounted prices on 30 of Pfizer's brand-name medications, offering savings to consumers on TrumpRx.

Generated by AI

Community

Of the messages about GDRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	80%	66.67%	50%	21.7%
Newcomers	20%	33.33%	50%	78.3%

Regulars· Oct 9

GoodRx Holdings, Inc. (GDRX) is in talks with the Trump administration regarding TrumpRx participation, a new site connecting consumers to drugmakers, pharmacies, and discount programs to help lower prescription costs.
The talks have led to a significant increase in GDRX stock price, with a spike of ~17% earlier in the week, and shares are trading higher after the company's announcement.
GoodRx's success will depend on navigating the evolving market, as stated by Bank of America, and the company's shares are being closely watched for updates on the Trump administration's TrumpRx initiative.

Newcomers· Feb 7

Newcomers to the GoodRx conversation are discussing its potential for disrupting Big Pharma, with some suggesting it could be a major player in the market.
The company's recent actions, such as a possible buyback and its relationship with TrumpRx, are being closely examined by newcomers, who are questioning the motivations behind these moves.
GoodRx's value proposition, including its ability to make prescription medication more affordable, is being compared to TrumpRx, which some view as a less effective alternative.

Generated by AI

GoodRx Holdings

Social

Jun 5

Bullish· Feb 26

Bearish· Feb 26

Earnings· May 9

Analysts· May 10

Announcements· Feb 6

Regulars· Oct 9

Newcomers· Feb 7

Amazon, GoodRx target US prescription subscribers as health insurance coverage slips

Mark Cuban’s Cost Plus vs. GoodRx vs. Amazon: Cheaper Prescription Options

InvestingPro Fair Value delivers 64% return on GoodRx in 5 months By Investing.com

GoodRx expands family healthcare plan with 250 free medications

GoodRx offers health subscription for families, to launch as employee benefit in 2027

GoodRx offers health subscription for families, to launch as employee benefit in 2027 By Reuters

Also Discussed

GoodRx Holdings, Inc. Class A Common Stock

Company Information

Location

Amazon, GoodRx target US prescription subscribers as health insurance coverage slips

Mark Cuban’s Cost Plus vs. GoodRx vs. Amazon: Cheaper Prescription Options

InvestingPro Fair Value delivers 64% return on GoodRx in 5 months By Investing.com

GoodRx expands family healthcare plan with 250 free medications

GoodRx offers health subscription for families, to launch as employee benefit in 2027

GoodRx offers health subscription for families, to launch as employee benefit in 2027 By Reuters

Also Discussed

Social

Jun 5

Bullish· Feb 26

Bearish· Feb 26

Earnings· May 9

Analysts· May 10

Announcements· Feb 6

Regulars· Oct 9

Newcomers· Feb 7